ICD-10-PCS Tabular Index · Section X · FY 2027 XW0

XW0 Introduction - Anatomical Regions ICD-10-PCS

The XW0 code range contains 179 ICD-10-PCS codes for Introduction procedures on the anatomical regions. 178 of the codes are billable and valid for inpatient claim submission in fiscal year 2027.

✓ Built from the official CMS FY 2027 datasetEffective Oct 1, 2026 – Sep 30, 2027

179

Procedure Codes

178

Billable Codes

XW0

Characters 1–3

Parent Body System

Root Operation Definition

Introduction: Putting in or on a therapeutic, diagnostic, nutritional, physiological or prophylactic substance except blood or blood products.

ICD-10-PCS

Codes in the XW0 Range 179 codes · 178 billable

179 of 179 shown

XW0 New Technology, Anatomical Regions, IntroductionNon-billable header
XW01318 Introduction of Daratumumab and Hyaluronidase-fihj into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8
XW01329 Introduction of Talquetamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9
XW01348 Introduction of Teclistamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8
XW0134C Introduction of Elamipretide into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 12 New
XW0136A Introduction of Dasiglucagon into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 10
XW013F5 Introduction of Other New Technology Therapeutic Substance into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5
XW013G6 Introduction of REGN-COV2 Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
XW013H6 Introduction of Other New Technology Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
XW013K6 Introduction of Leronlimab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
XW013L9 Introduction of Elranatamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9
XW013S6 Introduction of COVID-19 Vaccine Dose 1 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
XW013S9 Introduction of Epcoritamab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9
XW013T6 Introduction of COVID-19 Vaccine Dose 2 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
XW013TB Introduction of Rozanolixizumab-noli Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 11
XW013U6 Introduction of COVID-19 Vaccine into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
XW013V7 Introduction of COVID-19 Vaccine Dose 3 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7
XW013W5 Introduction of Caplacizumab into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5
XW013W7 Introduction of COVID-19 Vaccine Booster into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7
XW020D8 Introduction of Engineered Allogeneic Thymus Tissue into Muscle, Open Approach, New Technology Group 8
XW023S6 Introduction of COVID-19 Vaccine Dose 1 into Muscle, Percutaneous Approach, New Technology Group 6
XW023T6 Introduction of COVID-19 Vaccine Dose 2 into Muscle, Percutaneous Approach, New Technology Group 6
XW023U6 Introduction of COVID-19 Vaccine into Muscle, Percutaneous Approach, New Technology Group 6
XW023V7 Introduction of COVID-19 Vaccine Dose 3 into Muscle, Percutaneous Approach, New Technology Group 7
XW023W7 Introduction of COVID-19 Vaccine Booster into Muscle, Percutaneous Approach, New Technology Group 7
XW023Y7 Introduction of Other New Technology Monoclonal Antibody into Muscle, Percutaneous Approach, New Technology Group 7
XW03308 Introduction of Spesolimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 8
XW0330B Introduction of Alpha1-proteinase Inhibitor into Peripheral Vein, Percutaneous Approach, New Technology Group 11 New
XW0331B Introduction of Anitocabtagene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 11 New
XW0333A Introduction of Bentracimab, Ticagrelor Reversal Agent into Peripheral Vein, Percutaneous Approach, New Technology Group 10
XW0334A Introduction of Cefepime-taniborbactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 10
XW03357 Introduction of Narsoplimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW03358 Introduction of Mosunetuzumab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 8
XW0335A Introduction of Ceftobiprole Medocaril Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 10
XW03368 Introduction of Afamitresgene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 8
XW0336C Introduction of Landiolol Antiarrhythmic into Peripheral Vein, Percutaneous Approach, New Technology Group 12 New
XW03372 Introduction of Inactivated Coagulation Factor Xa into Peripheral Vein, Percutaneous Approach, New Technology Group 2
XW03378 Introduction of Tabelecleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 8
XW0337C Introduction of Zimislecel Allogeneic Stem Cell-Derived Islet Cell Therapy into Peripheral Vein, Percutaneous Approach, New Technology Group 12 New
XW03388 Introduction of Treosulfan into Peripheral Vein, Percutaneous Approach, New Technology Group 8
XW0338A Introduction of Obecabtagene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 10
XW03396 Introduction of Ceftolozane/Tazobactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW03398 Introduction of Inebilizumab-cdon into Peripheral Vein, Percutaneous Approach, New Technology Group 8
XW0339A Introduction of Odronextamab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 10
XW033A7 Introduction of Ciltacabtagene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033B3 Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 3
XW033BA Introduction of Orca-T Allogeneic T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 10
XW033C7 Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033CA Introduction of Zanidatamab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 10
XW033DA Introduction of Donislecel-jujn Allogeneic Pancreatic Islet Cellular Suspension into Peripheral Vein, Percutaneous Approach, New Technology Group 10
XW033E5 Introduction of Remdesivir Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 5
XW033F3 Introduction of Other New Technology Therapeutic Substance into Peripheral Vein, Percutaneous Approach, New Technology Group 3
XW033F5 Introduction of Other New Technology Therapeutic Substance into Peripheral Vein, Percutaneous Approach, New Technology Group 5
XW033FA Introduction of Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy into Peripheral Vein, Percutaneous Approach, New Technology Group 10
XW033FB Introduction of Valoctocogene Roxaparvovec-rvox into Peripheral Vein, Percutaneous Approach, New Technology Group 11
XW033G5 Introduction of Sarilumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5
XW033G6 Introduction of REGN-COV2 Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW033G7 Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033H5 Introduction of Tocilizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5
XW033H6 Introduction of Other New Technology Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW033H7 Introduction of Axicabtagene Ciloleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033J7 Introduction of Tisagenlecleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033K7 Introduction of Idecabtagene Vicleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033K9 Introduction of Sulbactam-Durlobactam into Peripheral Vein, Percutaneous Approach, New Technology Group 9
XW033L6 Introduction of CD24Fc Immunomodulator into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW033L7 Introduction of Lifileucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033M7 Introduction of Brexucabtagene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033MA Introduction of Emapalumab-lzsg Anti-IFNy Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 10
XW033N7 Introduction of Lisocabtagene Maraleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033NA Introduction of Tarlatamab-dlle Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 10
XW033P9 Introduction of Glofitamab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 9
XW033PB Introduction of Aztreonam-avibactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 11
XW033Q5 Introduction of Tagraxofusp-erzs Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 5
XW033Q9 Introduction of Posoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 9
XW033QB Introduction of Iloprost into Peripheral Vein, Percutaneous Approach, New Technology Group 11
XW033R9 Introduction of Rezafungin into Peripheral Vein, Percutaneous Approach, New Technology Group 9
XW033RB Introduction of Letetresgene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 11
XW033S5 Introduction of Iobenguane I-131 Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 5
XW033W5 Introduction of Caplacizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5
XW033WB Introduction of Fosfomycin Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 11
XW04308 Introduction of Spesolimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 8
XW0430B Introduction of Alpha1-proteinase Inhibitor into Central Vein, Percutaneous Approach, New Technology Group 11 New
XW0431B Introduction of Anitocabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 11 New
XW0433A Introduction of Bentracimab, Ticagrelor Reversal Agent into Central Vein, Percutaneous Approach, New Technology Group 10
XW0434A Introduction of Cefepime-taniborbactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 10
XW04357 Introduction of Narsoplimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 7
XW04358 Introduction of Mosunetuzumab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 8
XW0435A Introduction of Ceftobiprole Medocaril Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 10
XW04368 Introduction of Afamitresgene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 8
XW0436C Introduction of Landiolol Antiarrhythmic into Central Vein, Percutaneous Approach, New Technology Group 12 New
XW04372 Introduction of Inactivated Coagulation Factor Xa into Central Vein, Percutaneous Approach, New Technology Group 2
XW04378 Introduction of Tabelecleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 8
XW04388 Introduction of Treosulfan into Central Vein, Percutaneous Approach, New Technology Group 8
XW0438A Introduction of Obecabtagene Autoleucel into Central Vein, Percutaneous Approach, New Technology Group 10
XW04396 Introduction of Ceftolozane/Tazobactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6
XW04398 Introduction of Inebilizumab-cdon into Central Vein, Percutaneous Approach, New Technology Group 8
XW0439A Introduction of Odronextamab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 10
XW043A7 Introduction of Ciltacabtagene Autoleucel into Central Vein, Percutaneous Approach, New Technology Group 7
XW043B3 Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 3
XW043BA Introduction of Orca-T Allogeneic T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 10
XW043C7 Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
XW043CA Introduction of Zanidatamab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 10
XW043E5 Introduction of Remdesivir Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 5
XW043F3 Introduction of Other New Technology Therapeutic Substance into Central Vein, Percutaneous Approach, New Technology Group 3
XW043F5 Introduction of Other New Technology Therapeutic Substance into Central Vein, Percutaneous Approach, New Technology Group 5
XW043FA Introduction of Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy into Central Vein, Percutaneous Approach, New Technology Group 10
XW043FB Introduction of Valoctocogene Roxaparvovec-rvox into Central Vein, Percutaneous Approach, New Technology Group 11
XW043G5 Introduction of Sarilumab into Central Vein, Percutaneous Approach, New Technology Group 5
XW043G6 Introduction of REGN-COV2 Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6
XW043G7 Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
XW043H5 Introduction of Tocilizumab into Central Vein, Percutaneous Approach, New Technology Group 5
XW043H6 Introduction of Other New Technology Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6
XW043H7 Introduction of Axicabtagene Ciloleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
XW043J7 Introduction of Tisagenlecleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
XW043K7 Introduction of Idecabtagene Vicleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
XW043K9 Introduction of Sulbactam-Durlobactam into Central Vein, Percutaneous Approach, New Technology Group 9
XW043L6 Introduction of CD24Fc Immunomodulator into Central Vein, Percutaneous Approach, New Technology Group 6
XW043L7 Introduction of Lifileucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
XW043M7 Introduction of Brexucabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
XW043MA Introduction of Emapalumab-lzsg Anti-IFNy Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 10
XW043N7 Introduction of Lisocabtagene Maraleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
XW043NA Introduction of Tarlatamab-dlle Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 10
XW043P9 Introduction of Glofitamab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 9
XW043PB Introduction of Aztreonam-avibactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 11
XW043Q5 Introduction of Tagraxofusp-erzs Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5
XW043Q9 Introduction of Posoleucel into Central Vein, Percutaneous Approach, New Technology Group 9
XW043QB Introduction of Iloprost into Central Vein, Percutaneous Approach, New Technology Group 11
XW043R9 Introduction of Rezafungin into Central Vein, Percutaneous Approach, New Technology Group 9
XW043RB Introduction of Letetresgene Autoleucel into Central Vein, Percutaneous Approach, New Technology Group 11
XW043S5 Introduction of Iobenguane I-131 Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5
XW043W5 Introduction of Caplacizumab into Central Vein, Percutaneous Approach, New Technology Group 5
XW043WB Introduction of Fosfomycin Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 11
XW0534B Introduction of Somatic Stem Cells into Peripheral Artery, Percutaneous Approach, New Technology Group 11 New
XW053T9 Introduction of Melphalan Hydrochloride Antineoplastic into Peripheral Artery, Percutaneous Approach, New Technology Group 9
XW0632B Introduction of CPI-601 Enzyme Replacement Therapy into Cerebral Ventricle, Percutaneous Approach, New Technology Group 11 New
XW0DX38 Introduction of Maribavir Anti-infective into Mouth and Pharynx, External Approach, New Technology Group 8
XW0DX82 Introduction of Uridine Triacetate into Mouth and Pharynx, External Approach, New Technology Group 2
XW0DXF5 Introduction of Other New Technology Therapeutic Substance into Mouth and Pharynx, External Approach, New Technology Group 5
XW0DXJ9 Introduction of Quizartinib Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 9
XW0DXK8 Introduction of Sabizabulin into Mouth and Pharynx, External Approach, New Technology Group 8
XW0DXM6 Introduction of Baricitinib into Mouth and Pharynx, External Approach, New Technology Group 6
XW0DXN9 Introduction of SER-109 into Mouth and Pharynx, External Approach, New Technology Group 9
XW0DXVB Introduction of Xanomeline and Trospium Chloride into Mouth and Pharynx, External Approach, New Technology Group 11
XW0E33B Introduction of Lunsotogene Parvec-cwha via Intracochlear Infusion into Ear(s), Percutaneous Approach, New Technology Group 11 New
XW0G738 Introduction of Maribavir Anti-infective into Upper GI, Via Natural or Artificial Opening, New Technology Group 8
XW0G7K8 Introduction of Sabizabulin into Upper GI, Via Natural or Artificial Opening, New Technology Group 8
XW0G7M6 Introduction of Baricitinib into Upper GI, Via Natural or Artificial Opening, New Technology Group 6
XW0G886 Introduction of Mineral-based Topical Hemostatic Agent into Upper GI, Via Natural or Artificial Opening Endoscopic, New Technology Group 6
XW0H738 Introduction of Maribavir Anti-infective into Lower GI, Via Natural or Artificial Opening, New Technology Group 8
XW0H7K8 Introduction of Sabizabulin into Lower GI, Via Natural or Artificial Opening, New Technology Group 8
XW0H7M6 Introduction of Baricitinib into Lower GI, Via Natural or Artificial Opening, New Technology Group 6
XW0H7X8 Introduction of Broad Consortium Microbiota-based Live Biotherapeutic Suspension into Lower GI, Via Natural or Artificial Opening, New Technology Group 8
XW0H886 Introduction of Mineral-based Topical Hemostatic Agent into Lower GI, Via Natural or Artificial Opening Endoscopic, New Technology Group 6
XW0J3HA Introduction of Paclitaxel-Coated Balloon Technology, One Balloon into Coronary Artery, One Artery, Percutaneous Approach, New Technology Group 10
XW0J3JA Introduction of Paclitaxel-Coated Balloon Technology, Two Balloons into Coronary Artery, One Artery, Percutaneous Approach, New Technology Group 10
XW0J3KA Introduction of Paclitaxel-Coated Balloon Technology, Three Balloons into Coronary Artery, One Artery, Percutaneous Approach, New Technology Group 10
XW0J3LA Introduction of Paclitaxel-Coated Balloon Technology, Four or More Balloons into Coronary Artery, One Artery, Percutaneous Approach, New Technology Group 10
XW0K3HA Introduction of Paclitaxel-Coated Balloon Technology, One Balloon into Coronary Artery, Two Arteries, Percutaneous Approach, New Technology Group 10
XW0K3JA Introduction of Paclitaxel-Coated Balloon Technology, Two Balloons into Coronary Artery, Two Arteries, Percutaneous Approach, New Technology Group 10
XW0K3KA Introduction of Paclitaxel-Coated Balloon Technology, Three Balloons into Coronary Artery, Two Arteries, Percutaneous Approach, New Technology Group 10
XW0K3LA Introduction of Paclitaxel-Coated Balloon Technology, Four or More Balloons into Coronary Artery, Two Arteries, Percutaneous Approach, New Technology Group 10
XW0L3HA Introduction of Paclitaxel-Coated Balloon Technology, One Balloon into Coronary Artery, Three Arteries, Percutaneous Approach, New Technology Group 10
XW0L3JA Introduction of Paclitaxel-Coated Balloon Technology, Two Balloons into Coronary Artery, Three Arteries, Percutaneous Approach, New Technology Group 10
XW0L3KA Introduction of Paclitaxel-Coated Balloon Technology, Three Balloons into Coronary Artery, Three Arteries, Percutaneous Approach, New Technology Group 10
XW0L3LA Introduction of Paclitaxel-Coated Balloon Technology, Four or More Balloons into Coronary Artery, Three Arteries, Percutaneous Approach, New Technology Group 10
XW0M3HA Introduction of Paclitaxel-Coated Balloon Technology, One Balloon into Coronary Artery, Four or More Arteries, Percutaneous Approach, New Technology Group 10
XW0M3JA Introduction of Paclitaxel-Coated Balloon Technology, Two Balloons into Coronary Artery, Four or More Arteries, Percutaneous Approach, New Technology Group 10
XW0M3KA Introduction of Paclitaxel-Coated Balloon Technology, Three Balloons into Coronary Artery, Four or More Arteries, Percutaneous Approach, New Technology Group 10
XW0M3LA Introduction of Paclitaxel-Coated Balloon Technology, Four or More Balloons into Coronary Artery, Four or More Arteries, Percutaneous Approach, New Technology Group 10
XW0Q316 Introduction of Eladocagene exuparvovec into Cranial Cavity and Brain, Percutaneous Approach, New Technology Group 6
XW0Q35C Introduction of Ifezuntirgene Inilparvovec into Cranial Cavity and Brain, Percutaneous Approach, New Technology Group 12 New
XW0U0CC Introduction of Recombinant Human Bone Morphogenetic Protein-2 with Collagen Scaffold into Joints, Open Approach, New Technology Group 12 New
XW0U0GA Introduction of Vancomycin Hydrochloride and Tobramycin Sulfate Anti-Infective, Temporary Irrigation Spacer System into Joints, Open Approach, New Technology Group 10
XW0U0XB Introduction of Peptide Enhanced Bone Void Filler into Joints, Open Approach, New Technology Group 11
XW0U3XB Introduction of Peptide Enhanced Bone Void Filler into Joints, Percutaneous Approach, New Technology Group 11
XW0U4XB Introduction of Peptide Enhanced Bone Void Filler into Joints, Percutaneous Endoscopic Approach, New Technology Group 11
XW0V0BC Introduction of Vancomycin-eluting Bone Void Filler into Bones, Open Approach, New Technology Group 12 New
XW0V0P7 Introduction of Gentamicin-eluting Bone Void Filler into Bones, Open Approach, New Technology Group 7 Updated
XW0V3WA Introduction of AGN1 Bone Void Filler into Bones, Percutaneous Approach, New Technology Group 10

About the XW0 Code Range

These procedures put substances into or onto the body for treatment, diagnosis, nutrition, body functions, or prevention, excluding blood and blood products. They include cancer treatments, anti-infectives, and COVID-19 vaccines.

The fourth character identifies the site, such as muscle, a vein, or a coronary artery. Coronary artery values distinguish one, two, three, or four or more arteries. The fifth character identifies open, puncture, opening, or external access, including options with endoscopic viewing. The sixth names the substance or technology, such as remdesivir or an immunotherapy. The seventh identifies the New Technology Group.

FY 2027 changes: The FY 2027 ICD-10-PCS update, effective October 1, 2026, added XW0134C, XW0330B, XW0331B, XW0336C, XW0337C, XW0430B, XW0431B, XW0436C, XW0534B, XW0632B, XW0E33B, XW0Q35C and 2 other codes, revised the title of XW0V0P7 to "Introduction of Gentamicin-eluting Bone Void Filler into Bones, Open Approach, New Technology Group 7" (was "Introduction of Antibiotic-eluting Bone Void Filler into Bones, Open Approach, New Technology Group 7") and deleted XW00X27, XW01397, XW01X27, XW023X7, XW03367, XW03377, XW03387, XW033B7, XW04367, XW04377, XW04387, XW043B7 and 3 other codes.

Questions About This Page

How many billable codes are in the XW0 range?

Of the 179 codes in this range, 178 are billable and valid for inpatient claim submission from October 1, 2026 through September 30, 2027. Table header codes group them but cannot be reported on claims.

What does the XW0 range classify?

The range classifies Introduction procedures, putting in or on a therapeutic, diagnostic, nutritional, physiological or prophylactic substance except blood or blood products, performed on the anatomical regions. Each code adds the body part, approach, device, and qualifier in characters four through seven, and links to its own reference page.

Related References

All ICD-10-PCS Sections All of New Technology (X)All of Body System XW ICD-10-PCS Code Lookup ICD-10-CM Codes List MS-DRG Reference Medicare Code Edits

Source: CMS FY 2027 ICD-10-PCS order file and code tables, effective October 1, 2026 through September 30, 2027.